RxDoctor Payments DataLook up a doctor →

Yoel Drucker, MD

Rheumatology · Sarasota, FLNPI 1790760783

Payments from drug & device makers

$1,193,769in general payments, 2019–2025

Across 317 payments — averaging $3765.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$887K
  • Novartis$233K
  • Kiniksa Pharmaceuticals, Ltd.$20K
  • Eli Lilly$17K
  • Sanofi US Services Inc.$17K
  • Gilead$11K
  • plus $9K from 13 others

What the payments were for

  • Travel & lodging$1,61823%
  • Food & beverage$5,53977%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,193,769 in reported general payments places this provider in the 90th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$1,104,592
Medicare patients
693
Services billed
62,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab45$307,572
EnbrelEtanercept12$87,683
OtezlaApremilast19$87,667
Humira(Cf)Adalimumab11$71,825
ActemraTocilizumab14$33,741
MethotrexateMethotrexate Sodium371$11,350
Hydroxychloroquine Sulfate318$8,986
Cevimeline Hcl35$6,134
Leflunomide67$3,601
Prednisone381$2,758
Azathioprine40$1,512
Gabapentin65$1,250
Colchicine30$1,138
Sulfasalazine DrSulfasalazine27$1,090
Risedronate Sodium20$1,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$576$175,35031 claims
AbbVieHumira(Cf)$805$71,82511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →